The recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the phase III OnTarget trial indicate that crofelemer (Mytesi, Fulyzaq) achieved statistical significance in this subgroup.
City of Hope launched a national clinical trials model to expand access to emerging life-saving cancer treatments to more patients across the country.
